SUCCIPRO

SUCCIPRO is a pioneering biotechnology research company focused on developing innovative succinate-modulating therapies. Specializing in addressing inflammatory and metabolic disorders, SUCCIPRO is dedicated to creating first-in-class molecules that can effectively modulate succinate, a metabolite known for its pro-inflammatory properties which are elevated in numerous metabolic and inflammatory conditions.

Located at Mallafre Guasch 4 in Tarragona, ES, SUCCIPRO is advancing a diversified pipeline of candidates currently in the early preclinical phase. The company is actively exploring various clinical indications, including Type 2 Diabetes, obesity, Inflammatory Bowel Disease, and Non-Alcoholic Steatohepatitis, demonstrating a commitment to tackling significant health challenges.

SUCCIPRO is poised for significant growth and impact in the biotechnology sector. We invite the manager of SUCCIPRO to create a customized and exclusive company showcase and product listing on our platform, enhancing its visibility and reach within the industry.